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Development of orthotopic tumour 
models using ultrasound-guided 
intrahepatic injection
L. e. McVeigh1, I. Wijetunga1, N. Ingram  1, G. Marston1, R. prasad2, A. F. Markham1 & 
p. L. Coletta1
Mouse models of human diseases are an essential part of the translational pipeline. orthotopic tumour 
mouse models are increasingly being used in cancer research due to their increased clinical relevance 
over subcutaneous xenograft models, particularly in relation to metastatic disease. In this study, we 
have developed orthotopic colorectal cancer liver metastases (CRCLM) and primary cholangiocarcinoma 
(CCA) models in BALB/c nude mice using minimally invasive ultrasound-guided intrahepatic injection. 
Due to its minimally invasive nature, the method reduced risk from surgical complications whilst being 
fast and easy to perform and resulted in measurable tumour volumes 1 to 3 weeks post-injection. 
tumour volumes were monitored in vivo by weekly high-frequency ultrasound (HF-Us) and/or twice 
weekly bioluminescence imaging (BLI) and confirmed with end-point histology. Take rates were high 
for human CRC cells (>73%) and for CCA cells (90%). We have demonstrated that this method reliably 
induces CRCLM and CCAs, in which tumour volume can be monitored throughout using HF-Us and/
or BLI. this provides a promising experimental tool for future testing of cancer therapeutics in an 
orthotopic model.
Metastatic cancer is the leading cause of death for patients diagnosed with colorectal cancer (CRC) with a five-year 
survival of stage-IV disease at diagnosis just 7–8%1. The most common site of metastasis is the liver, amounting to 
70% of all cases2. Cholangiocarcinoma (CCA) although relatively rare, has a five-year survival of approximately 
5%3. Both are characterised as being difficult to treat with poor long-term survival of patients. Therefore, there 
is a pressing need for more reliable models of these diseases for pre-clinical evaluation of anti-cancer therapies. 
Currently, orthotopic models recapitulating these human cancers are time-consuming to establish with poor or 
unreliable tumour formation.
In CRC, cancer cells from the primary tumour disseminate via the haematogenous route to secondary sites 
in the liver4,5. Mouse models of CRC and/or liver metastases are either transplantable or genetically modified, 
with the latter generally taking a long time to establish and rarely metastasise6,7. Transplantable models are much 
faster to generate but involve direct surgical implantation of cancer cells or tissues into the caecum or spleen, or 
direct injection into the portal vein8–11. The most commonly exploited models of colorectal cancer liver metas-
tases (CRCLM) are injection site-dependant, either by surgical inoculation of the spleen or caecum involving 
implantation or subserosal injection12,13. Intrasplenic injection results in the rapid formation of liver tumours 
by drainage into the hepatic portal vein via the splenic vein but often involves the removal of the spleen; a vital 
immune organ. Caecal injections are technically more challenging with a higher risk of post-surgical complica-
tions, but with the advantage of allowing the study of invasion from the primary site. However, this results in the 
slow (up to four months) and unreliable formation of metastases in the liver in addition to lung, lymph nodes and 
peritoneal tumours10.
Pre-clinical orthotopic models of CCA generally involve chemotoxic agents or gene knock-out techniques14,15. 
The process of generating these models is generally long and expensive. A syngeneic rat model of intrahepatic 
CCA using a rat-derived CCA cell line surgically implanted into the left hepatic duct with/without surgical liga-
tion of the bile duct, reported 100% success rates16. Although this model has the advantage of producing bile duct 
obstruction (which is a common feature of CCA), the development of the model involved invasive surgery and 
does not utilise human-derived cancer cells.
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The tumour microenvironment is thought to play an important role in influencing the growth, response to 
treatment and tumour immune responses in vivo17–19. Tumours grown subcutaneously do not accurately repre-
sent the natural tumour microenvironment which contains fibroblasts, immune cells and an extracellular matrix 
which have all been shown to be influencing factors for tumour establishment and growth20. Subcutaneous mod-
els, in general, have been poor predictors of drug efficacy in humans and therefore the need for more predictive 
models of human cancers21. Hence, the generation of in vivo models of advanced disease in an orthotopic setting 
are necessary for more effective translation of novel therapies in order to improve treatment outcomes. Immune 
compromised or competent mice can be used depending on the cell lines used (patient-derived and/or human 
xenografts or syngeneic grafts) for testing of cytotoxic or immunotherapies, respectively.
To this end, we have developed a minimally-invasive method to create orthotopic liver tumours that recapit-
ulate cancers in the liver. Ultrasound-guided percutaneous injections were used to develop a pre-clinical ortho-
topic model of CRCLM, which was minimally-invasive, fast and easy to perform and was amenable to monitoring 
tumour growth regularly and economically via HF-US. The human colorectal adenocarcinoma cell line, SW620, 
that was first derived from a lymph node metastasis was used with or without Matrigel in BALB/c nude mice to 
assess the feasibility of generating CRCLM. TFK-1, an extra-hepatic CCA cell line transfected to express lucif-
erase (TFKLuc2B2), was used for the generation of an orthotopic CCA model which had the advantage of longi-
tudinal tumour growth monitoring using BLI as well as HF-US imaging.
Results
Development of an orthotopic model of CRCLM. An orthotopic human CRCLM mouse model was 
developed using ten 5-week-old female BALB/c nude mice. Mice were randomised into two groups of five and 
anaesthetised with 5% (v/v) isoflurane gas in medical air at a flow rate of 2 L/min via an induction chamber, then 
positioned supine on the ultrasound platform with a nose cone for and maintained at 3% (v/v). Ultrasound gel 
was applied liberally to the abdomen and mice were imaged in B mode (2D) using a 40 MHz (RM-704) transducer 
with the VisualSonics Vevo 770 system, to determine and visualise the largest liver lobe (Fig. 1a). A 1 ml Terumo 
Myjector 29-gauge insulin syringe with a fixed 1.27 cm needle (Terumo, Tokyo, Japan) was aligned and advanced 
into the liver by freehand using the ultrasound monitor for reference. A 40 µl bolus of 20,000 SW620 CRC cells 
suspended in either PBS:Matrigel (1:1 v/v) or PBS alone was injected directly into the liver at a depth of 3 mm 
Figure 1. Representative images of ultrasound-guided intrahepatic injections and subsequent tumour. (a) 
HF-US image of mouse liver pre-injection. Skin reflection is an artefact indicated by the dashed line. (b) 
Intrahepatic injection of a 40 µl bolus of human CRC cells using a 29-gauge needle to a depth of 3 mm. Care 
was taken to avoid major blood vessels. (c) A 3D reconstruction (matrix) of the final orthotopic tumour volume 
35 days after tumour inoculation. The 3D scans of tumours were performed by HF-US using a 40 MHz (RM-
704) transducer on a motorised arm, with the VisualSonics Vevo 770 system. The 3D reconstructions were 
generated post-acquisition using the Vevo 770 version 3 software. (d) Dissection of the same mouse revealed 
no peritoneal disease, with normal organ colour and an obvious single tumour at injection site. Enlarged region 
shows the dissected liver with an orthotopic tumour. T = tumour, L = liver (tumour region circled with dashed 
line).
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(Fig. 1b). A deliberate 30-second pause before the needle was retracted allowed for complete delivery of cells into 
the liver, to prevent recoil of cells and leakage into the peritoneum. A video showing an ultrasound-guided injec-
tion is included in the Online Resource 1.
Post-injection, anaesthesia was ceased and mice were placed in a warm recovery chamber and observed until 
fully recovered then returned to their original housing. The whole procedure from induction of anaesthesia 
to recovery took less than five minutes. Animals’ heart and respiration rates were monitored during the entire 
procedure through electrode pads on the ultrasound platform using the Vevo’s Physiological Controller Unit. 
Post-operative analgesics were not necessary with such a minimally-invasive technique. One mouse from the 
Matrigel group did not recover post-procedure for unknown reasons.
Due to the internal location of the tumours, tumour volume was monitored by HF-US imaging. The condition 
of each animal was monitored by daily visual inspection for clinical signs of pain or distress such as abnormal 
behaviours, piloerection, reduced mobility, body posture or isolation from cage mates. The Mouse Grimace Scale 
was also used to assess each animal for signs of pain. All indicators suggested that the animals were in minimal 
discomfort, if any, after this technique. Animals were weighed weekly and if they lost >10% of pre-experimental 
body mass, would be monitored daily. If weight loss reached 20%, animals would be humanely euthanised, how-
ever, in this case, all animals remained at a healthy weight throughout.
orthotopic CRCLM tumour growth. Orthotopic tumours were imaged weekly by HF-US for longitudinal 
monitoring of tumour growth. 3D-mode imaging acquisition was used, with the minimum step size possible 
for the length of tumour. The 3D reconstructions were generated post-acquisition using the Vevo 770 version 3 
software (Fujifilm VisualSonics). Tumour volume was calculated by outlining the tumour area of multiple 2D sec-
tions at regular intervals by-hand throughout the image scan, which generated a 3D reconstruction and tumour 
volume. Animals were euthanised 35 days post-inoculation. Figure 1c shows an HF-US image of mouse liver 
bearing a single tumour acquired at end-point. After 35 days, mice had large singular tumours (Fig. 1d) with 
obvious distended abdomens. Tumour volumes were plotted over time (Fig. 2a) and final volumes are shown 
in Table 1. Based on in vivo HF-US imaging, the orthotopic xenograft take rate was 100% using Matrigel (after 
exclusion of the procedure-related mortality) and 20% without. One of the tumours without the use of Matrigel 
grew lower down in the liver and was out of the imaging region and upon dissection take rate was recalculated to 
40%. Tumour doubling times for tumours with or without Matrigel were 3.9 ± 1.2 days compared to 3.4, respec-
tively, with no statistically significant differences between groups, suggesting Matrigel did not influence tumour 
growth rate in this model. End-point liver mass was used to determine any significant differences between livers 
with orthotopic tumours and those with no tumours (Fig. 2b). Although small numbers of animals were used 
in this study, the significant difference obtained suggests the robustness of this technique. Livers with tumours 
had a significantly higher mass than those without, p = 0.048 (Mann Whitney, two-tailed). Tumour microvessel 
density was determined and was not statistically significantly different between groups, suggesting Matrigel did 
not influence blood vessel formation after 35 days (Fig. 2c). Body mass prior to procedure up to end-point was 
not statistically significantly different at any point during the experiment, indicating good health and well-being 
throughout (Fig. 2d).
Histological examination of CRCLM. By histology, tumours were observed in 4/4 (100%) of livers 
injected with cells in Matrigel and 2/5 (40%) without Matrigel (Table 1). The use of Matrigel may initially hold 
cells at the injection site by the formation of a plug and prevent leakage as seen where HF-US imaging missed one 
tumour due to its low positioning, potentially due to this reason.
Figure 2e–g show representative H&E staining of mouse livers containing an orthotopic tumour. Livers 
were analysed by H&E staining of paraffin-embedded fixed tissue and revealed single tumours with distinct 
liver-tumour borders. Orthotopic tumours characteristically had necrotic islands and areas of geographic necro-
sis with poor glandular differentiation and mainly formed sheets of epithelial cells, typical of SW620 tumours22. 
Invasive borders into the liver parenchyma were common, with inflammatory infiltrate and blood pooling in 
the sinusoids of the liver an indication of potential vascular congestion, which is often seen with liver cancers23 
(Fig. 2g). The endothelial cell marker CD31 was used to immunolabel blood vessels of the tumour and liver and 
indicated how much more vascularised liver was compared to tumour (Fig. 2h).
Independent validation of the CRCLM model. This ultrasound-guided injection technique was inde-
pendently validated by a second ultrasound operator using 15 5 to 7-week-old male BALB/c nude mice using 
Matrigel with the injection. All mice survived inoculation with weight monitoring and general health showing the 
procedure was well tolerated throughout. Animals were euthanised 47 days post-inoculation. This second cohort 
resulted in a take rate of 73% (11/15). Weekly HF-US imaging was used for longitudinal monitoring of tumour 
growth (Fig. 3). Mean (± SEM) tumour volume of 119.2 (± 25.3) mm3 was determined at end-point, with a mean 
tumour doubling time of 4.5 days.
Development of an orthotopic model of primary cholangiocarcinoma (CCA). With the success 
and ease of this method for generation of CRCLM, the same technique was implemented to produce an ortho-
topic model of primary CCA. Ten 6 to 10-week-old female BALB/c nude mice were injected as described above 
with a 50 µl bolus of 5 million TFKLuc2B2 cells in PBS using HF-US (Matrigel not used). The gallbladder was 
used as a landmark for ultrasound-guided percutaneous injection into the liver as it was the closest relevant 
structure to the bile duct which could be located using ultrasound (Fig. 4a and Online resource 2). Animals were 
euthanised 19 days post-inoculation, and at end-point tumour take rate was 90% (9/10), two animals also had 
discrete intra-peritoneal tumours and one of these also had a subcutaneous tumour at the injection site (Online 
Resource 3). HF-US imaging was performed weekly and the median (± range) tumour volume was determined 
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as 21.2 (9.0–32.5) mm3 14 days post-injection (n = 6). Figure 4b shows a representative HF-US 3D tumour recon-
struction image with the gallbladder nearby. At end-point, mice had tumours in the liver in close proximity to the 
gallbladder (Fig. 4c) and histological evaluation confirmed the presence of intrahepatic tumours close (<2 mm) 
to the gallbladder (Fig. 4d,e). One mouse was sacrificed at day 16 due to weight loss and abnormal behaviour. An 
orthotopic tumour was evident at necropsy with no obvious metastatic burden or cause of sudden deterioration.
In addition to HF-US imaging, bioluminescence imaging (BLI) was also performed up to twice weekly (Fig. 5), 
demonstrating an additional imaging modality for longitudinal monitoring of tumour burden in this model.
Discussion
To the best of our knowledge, this is the first known demonstration of non-surgical, orthotopic models of human 
CRCLM and primary CCA using ultrasound-guided intrahepatic injection. This method was minimally inva-
sive thereby reducing risk from surgical complications, whilst fast and easy to perform resulting in measurable 
tumour volumes 1–3 weeks later. No loss in body mass or changes to normal behaviour were noted at any point 
during the experiments, with the exception of one CCA mouse at day-16. The use of a 29-gauge needle to inject 
Figure 2. In vivo and ex vivo analysis of orthotopic SW620 liver tumour growth. (a) Graph of orthotopic 
growth measured in vivo by HF-US. (b) End-point liver mass (median ± 95% confidence interval) was 
statistically significantly different from livers with orthotopic tumours compared to those with no tumours 
*p = 0.048 (Mann-Whitney two-tailed). (c) Microvessel density was determined using the endothelial cell 
marker CD31 to immunolabel tumour blood vessels (median ± 95% confidence interval). (d) The body mass 
of the mice throughout the experiment (mean ± standard deviation). (e–g) Mouse livers with SW620 human 
CRC tumours were stained with H&E to reveal invasive boarders (dashed line) between liver (L) and tumour 
(T). Necrotic regions of tumour were common using this cell line (dotted line). (g) Red blood cells pooling 
in sinusoids (arrows) with inflammatory infiltrate (circled). (h) The endothelial cell marker CD31 was used 
to immunolabel blood vessels (arrows) of the tumour and liver and showed that the liver provided a highly 
vascularised microenvironment for the CRCLM tumour.
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cells resulted in no visible wound, an advantage over surgical inoculation which would require stitches, resulting 
in less inflammation and minimal healing time with this method. It has been widely suggested that pain and 
resulting stress can impact experimental outcomes resulting in poor reliability and reproducibility of experiments 
involving animals24. This model is therefore, an excellent example of the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research principles involving refinement of technique and development 
of techniques which minimise the ‘pain, suffering, distress or lasting harm’, directly improving welfare of animals 
in research25. This model represents a refinement of current technique with fewer animals required than with 
traditional orthotopic models of CRC, as tumour take rates were high and subsequent growth could be monitored 
longitudinally and non-invasively.
Tumour burden consisted of obvious, large tumours at/near the injection site, with minimal dissemination 
into the abdominal cavity, a distinct advantage for interventional studies. The necessity of Matrigel may be cell 
line dependent, it was not necessary for tumour growth and was not used for the CCA cell line TFKLuc2B2, but 
was however shown to improve SW620 orthotopic rates from 40% to 73–100%. Matrigel is comprised of extracel-
lular matrix proteins, collagen IV and growth factors which can be used to improve cell engraftment in difficult 
to grow cell lines or primary patient-derived cancer cells26,27. Due to the small volumes that could be injected into 
the intrahepatic space, reduced cell numbers could be used (compared to subcutaneous tumour models) and the 
Matrigel may have provided a more favourable environment for growth. The Matrigel may also have held the cells 
in place by the formation of a plug (Matrigel solidifies rapidly above 10°C) therefore preventing leakage of cells 
from the injection site, as seen in the group without Matrigel. Recently, a group has successfully demonstrated 
surgical intrahepatic inoculation of hepatocellular carcinoma cells with 100% take rates, however, 50% of these 
Mouse
Tumour volume (mm3)
With Matrigel Without Matrigel
1 93.2 81.6
2 81.4 N/O
3 54.1 N/T
4 30.3 N/T
5 N/R N/T
Take rate 4/4 (100%) 2/5 (40%)
Median volume (mm3) 67.7 81.56
Median doubling time (days) 3.9 3.4
Table 1. 3D volume measurements of orthotopic CRC tumours by HF-US, take rates and tumour doubling 
time. Take rates and final tumour volumes 35 days after tumour inoculation. N/R = non-recovery from 
anaesthesia, N/O = tumour not observed by US due to low position, N/T = no tumours. Median value given 
where possible.
Figure 3. Orthotopic CRCLM tumour growth curve. This technique was independently validated by a second 
ultrasound operator using Matrigel with ultrasound-guided intrahepatic injection of SW620s and resulted in 
a take rate of 73% (11/15). Weekly HF-US imaging was used for longitudinal monitoring of tumour growth. 
At 47 days post-inoculation (end-point), tumour volume was determined as 119.2 ± 25.3 mm3 (mean ± SEM) 
with a mean tumour doubling time of 4.5 days.
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also showed abdominal and pelvic tumours from leakage during intrahepatic injection or potentially a cell line 
specific result28. The non-surgical transplantation of CRC cells into liver has not been done before, but ortho-
topic pancreatic and bladder cancer models have been successfully developed using ultrasound-guided injection, 
demonstrating the diversity of models which can be created using minimally invasive methods29,30.
HF-US and BLI were used to identify the location of tumours and to monitor the progress of tumour growth 
in vivo. Both are relatively cheap, quick and safe imaging modalities as demonstrated here. Without the use of 
imaging, the outcome may not be known until end-point dissection and histological analysis, which would be 
time-consuming and require many more mice to determine appropriate end-points. As shown here, end-point 
liver mass can also be used to quantitate the degree of CRCLM tumour growth, as livers with tumours increased 
in mass significantly compared to those without. Other imaging modalities such as BLI (as shown here), magnetic 
resonance imaging, micro computed tomography or fluorescence31–33 may also be used for in vivo tumour volume 
assessment but may not be as economical, rapid or as accurate as HF-US for measurement of tumour volumes in 
vivo34.
Orthotopic tumours grow differently to the commonly used subcutaneous models and therefore the impor-
tance of using a model which takes into consideration the cancers natural microenvironment is vital for faster 
and more reliable clinical translation. The formation of large single tumours could reflect late-stage CRC, where 
large tumours in the liver would require de-bulking (i.e. obstructing portal vein) via adjuvant chemotherapy or 
radiation, prior to surgical resection. This model provides a promising experimental tool for future testing of 
anti-cancer agents for the management of metastatic CRC or primary CCA with the possibility of primary liver 
tumours such as hepatocellular carcinoma, hepatoblastoma or liver metastases from other cancers. The use of 
syngeneic cell lines in immunocompetent mice or patient-derived cells in immunodeficient mice should also be 
possible using this method and requires further evaluation.
In summary, this method has successfully demonstrated the development of a minimally-invasive model of 
CRCLM and CCA. The relatively quick and reliable formation of tumours allows for ease of monitoring of tumour 
volume via HF-US or BLI, and therefore a means of testing efficacy of novel therapeutics quickly and easily. This 
model provides a promising experimental tool for future testing of anti-cancer agents in an orthotopic setting.
Figure 4. Representative images of HF-US imaging and subsequent orthotopic CCA tumours. (a) HF-US 
image of mouse liver prior to inoculation. The gallbladder (GB) was used as a landmark for injection. Portal 
vein (PV) also shown. (b) 3D reconstruction (matrix) of orthotopic tumour volume (day 14 post-inoculation) 
with gallbladder (arrow). 3D scans of tumours were performed using HF-US using a 40 MHz (RM-704) 
transducer on a motorised arm, with the VisualSonics Vevo 770 system. The 3D reconstructions were generated 
post-acquisition using the Vevo 770 version 3 software. (c) Representative mouse liver at end-point (19 days). 
Tumour (T) in close proximity to gallbladder (GB) indicated. (d,e) Liver (L) sections of two orthotopic tumours 
stained with H&E to demonstrate proximity of orthotopic tumour (<2 mm) to gallbladder (GB).
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Methods
Cell culture. The SW620 cell line was originally obtained from the American Type Culture Collection 
(ATCC). Human extrahepatic CCA cells TFK-1 (originally derived from mid-bile duct tumour35) were trans-
fected with luciferase for bioluminescence imaging, clones were selected and one was termed TFKLuc2B2. Cells 
were regularly screened for mycoplasma and were short random repeat (STR) DNA profile authenticated. Cells 
were maintained in vented T150 tissue culture flasks (Corning Life Sciences, UK) using Roswell Park Memorial 
Institute medium 1640 (RPMI Medium 1640, Gibco™) supplemented with 10% (v/v) foetal calf serum (FCS) 
(Invitrogen, UK) at 37°C in a 5% CO2 atmosphere. Cells were passaged at 70–80% confluence by washing with 
sterile phosphate buffered saline (PBS) pH 7.4 (Invitrogen, UK) before being harvested by trypsinisation. Culture 
medium was added back into the flask to block the action of trypsin before cells were collected and centrifuged 
at 400 g for 5 minutes using an Eppendorf™ 5810 R centrifuge (Eppendorf™ Hamburg, Germany). Cells were 
re-suspended in PBS and the total cell count was obtained manually using a Neubauer haemocytometer, and the 
concentration adjusted using PBS. SW620 cells were further adjusted to 5 × 105 cells/ml using ice-cold Matrigel 
(Geltrex™ LDEV-free reduced growth factor basement membrane matrix without phenol red, Life Technologies) 
or PBS immediately prior to injection. TFKLuc2B2 cells were adjusted to 1 × 108 cells/ml using PBS prior to 
injection.
Animals. BALB/c nude mice were originally obtained from Charles River Laboratories (Kent, UK) and main-
tained in-house. All mice were maintained under high health status conditions and were specific pathogen free 
status. Animals were housed in individually ventilated cages with access to food and water ad libitum. All proce-
dures were approved by the UK Home Office and carried out according to the Animals (Scientific Procedures) 
Act 1986.
HF-Us imaging. HF-US was performed weekly in the CRCLM model and at 3 weeks for the CCA model 
to measure tumour volume. Using a Vevo 770 HF-US system (Fujifilm VisualSonics, Inc, Ontario, Canada) a 
40 MHz (RM-704) transducer (VisualSonics, Inc, Ontario, Canada) was held above the animal in supine posi-
tion36, and imaged in B mode. Vevo 770 version 3 software (Fujifilm VisualSonics, Inc, Ontario, Canada) was 
used for post-acquisition 3D reconstructions and used to calculate tumour volumes37. A video showing HF-US 
imaging of a CRCLM tumour is included in the Online Resource 4.
Bioluminescence imaging (BLI). For in vivo BLI of CCA tumours, 150 mg/kg of D-Luciferin (Promega, 
Madison, WI, USA) was administered intraperitoneally five minutes prior to imaging using an IVIS Spectrum 
(PerkinElmer, Inc. Waltham, MA, USA). Auto-exposure settings were used with a maximum exposure time of 
Figure 5. Longitudinal bioluminescence imaging on days 7, 12, 14 and 19. The scale bar indicated standardised 
radiance across the imaging sessions. The animal shown in Column E did not show significant bioluminescence 
signal during the longitudinal imaging sessions and no demonstrable tumour by HF-US or post-sacrifice 
necropsy. Columns B, F and J showed comparatively low signals and corresponding smaller tumours. All 
other animals had easily demonstrable liver tumours. Animal H was sacrificed on day 16 due to the display of 
abnormal behaviour.
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one minute. Living image software version 4.4 (PerkinElmer, Inc. Waltham, MA, USA) was used to analyse bio-
luminescence signals. Standardised regions of interest were used to calculate average radiance (photons/second/
cm2/steradian) across imaging sessions.
Histology. Immediately after sacrifice by cervical dislocation, livers were collected and washed in ice-cold 
PBS, weighed and fixed by immersion in 4% (w/v) paraformaldehyde. Tissues were blocked in paraffin wax, 
5 µm sections cut and stained with Haematoxylin and Eosin (H&E, Sigma, UK) for visual examination. Images 
were obtained using an Eclipse E1000 light microscope and NIS-Elements BR software (Nikon Instruments Inc., 
Tokyo, Japan).
Immunohistochemistry. CD31-positive blood vessels were stained following the manufacturer’s instruc-
tions. In brief, sections were deparaffinised and heat-mediated antigen retrieval in 10 mM citrate buffer (pH6) 
was performed for 10 minutes. Endogenous peroxidases were blocked with 0.3% v/v hydrogen peroxide fol-
lowed by blocking of endogenous avidin/biotin (Vectorlabs, Burlingame, USA). Sections were then incubated 
for 1-hour with the primary antibody (1:20 rat anti-mouse CD31, clone SZ31, Dianova GmbH, Germany). 
After washing, a biotinylated anti-rat secondary antibody was applied for 30 minutes (1:200 Dako, UK). ABC/
HRP solutions (ABC/HRP Complex Kit, Vectorlabs, Burlingame, USA) were then applied and visualised with 
3,3′-Diaminobenzidine (DAB, Dako, UK). Slides were scanned using an Aperio slide scanner (Leica Biosystems, 
Wetzlar, Germany) at × 20 magnification. Ten 0.25 mm2 boxes were placed randomly throughout the tumour sec-
tion using RandomSpot software version 6.0238 and the number of CD31 positive vessel were counted manually. 
Microvessel density was calculated as the number of CD31 positive vessels per mm2.
statistical analyses. All statistical analyses were performed using GraphPad Prism 7 (©2017 GraphPad 
Software, Inc., CA, USA). The type of analysis used in each experiment and statistical significance are shown in 
figure legends.
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